Could a common seizure drug help schizophrenia patients lose weight and feel better?
NCT ID NCT02808533
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding topiramate (a seizure medication) to clozapine can help with weight loss and improve symptoms in people with treatment-resistant schizophrenia or schizoaffective disorder. About 50 overweight or obese adults aged 17-59 who are already on clozapine will receive either topiramate or a placebo. Researchers will track weight, insulin sensitivity, and psychiatric symptoms over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Topiramate (also known as Topamax)
What this could lead to
If it works, this could offer a way to manage weight gain and possibly improve psychiatric symptoms in people with hard-to-treat schizophrenia.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply widely. Topiramate can cause side effects like dizziness or cognitive issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Addiction and Mental Health
Toronto, Ontario, M5T 1R8, Canada